These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18996127)

  • 1. Frequencies of human influenza-specific antibody secreting cells or plasmablasts post vaccination from fresh and frozen peripheral blood mononuclear cells.
    Kyu SY; Kobie J; Yang H; Zand MS; Topham DJ; Quataert SA; Sanz I; Lee FE
    J Immunol Methods; 2009 Jan; 340(1):42-7. PubMed ID: 18996127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization.
    Halliley JL; Kyu S; Kobie JJ; Walsh EE; Falsey AR; Randall TD; Treanor J; Feng C; Sanz I; Lee FE
    Vaccine; 2010 Apr; 28(20):3582-7. PubMed ID: 20298818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques.
    Jegaskanda S; Amarasena TH; Laurie KL; Tan HX; Butler J; Parsons MS; Alcantara S; Petravic J; Davenport MP; Hurt AC; Reading PC; Kent SJ
    J Virol; 2013 Dec; 87(24):13706-18. PubMed ID: 24109221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination.
    Islam S; Mohn KG; Krammer F; Sanne M; Bredholt G; Jul-Larsen Å; Tete SM; Zhou F; Brokstad KA; Cox RJ
    Vaccine; 2017 Oct; 35(42):5666-5673. PubMed ID: 28899626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
    Loebermann M; Voss U; Meyer S; Bosse D; Fritzsche C; Klammt S; Frimmel S; Riebold D; Reisinger EC
    PLoS One; 2013; 8(8):e70866. PubMed ID: 23976960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of influenza vaccine immunogenicity using influenza antigen microarrays.
    Price JV; Jarrell JA; Furman D; Kattah NH; Newell E; Dekker CL; Davis MM; Utz PJ
    PLoS One; 2013; 8(5):e64555. PubMed ID: 23734205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro.
    Hendin HE; Pillet S; Lara AN; Wu CY; Charland N; Landry N; Ward BJ
    Vaccine; 2017 May; 35(19):2592-2599. PubMed ID: 28389100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
    Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
    Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired immune responses to the seasonal trivalent influenza vaccination in COPD.
    Staples KJ; Williams NP; Bonduelle O; Hutton AJ; Cellura D; Marriott AC; Combadière B; Wilkinson TMA
    Clin Exp Immunol; 2019 Oct; 198(1):71-82. PubMed ID: 31161649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers.
    Jacobson RM; Grill DE; Oberg AL; Tosh PK; Ovsyannikova IG; Poland GA
    Hum Vaccin Immunother; 2015; 11(4):961-9. PubMed ID: 25835513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Heterologous Prime-Boost Vaccination with H3N2 Influenza Viruses in Pre-Immune Individuals: Studies in the Pig Model.
    Chepkwony S; Parys A; Vandoorn E; Chiers K; Van Reeth K
    Viruses; 2020 Sep; 12(9):. PubMed ID: 32882956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.
    Li GM; Chiu C; Wrammert J; McCausland M; Andrews SF; Zheng NY; Lee JH; Huang M; Qu X; Edupuganti S; Mulligan M; Das SR; Yewdell JW; Mehta AK; Wilson PC; Ahmed R
    Proc Natl Acad Sci U S A; 2012 Jun; 109(23):9047-52. PubMed ID: 22615367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination.
    Wang W; Chen Q; Ford-Siltz LA; Katzelnick LC; Parra GI; Song HS; Vassell R; Weiss CD
    Clin Infect Dis; 2019 May; 68(12):2067-2078. PubMed ID: 30256912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.
    Allen JD; Ross TM
    J Virol; 2022 Apr; 96(7):e0165221. PubMed ID: 35289635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults.
    Stevanovic G; Lavadinovic L; Filipovic Vignjevic S; Holt R; Ilic K; Berlanda Scorza F; Sparrow E; Stoiljkovic V; Torelli G; Madenwald T; Socquet M; Barac A; Ilieva-Borisova Y; Pelemis M; Flores J
    Hum Vaccin Immunother; 2018 Mar; 14(3):579-586. PubMed ID: 29239682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localized mucosal response to intranasal live attenuated influenza vaccine in adults.
    Barría MI; Garrido JL; Stein C; Scher E; Ge Y; Engel SM; Kraus TA; Banach D; Moran TM
    J Infect Dis; 2013 Jan; 207(1):115-24. PubMed ID: 23087433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.